Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erythromycin

FDA-approved product (ointment, ophthalmic), marketed as A/T/S, Akne-Mycin, C-Solve-2 and 34 more.

Registered studies
50+
Lab records
32
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erythromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Eye infection
  • Infection
  • Whooping cough

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Macrolides; Antibiotics
FDA pharmacologic class
Macrolide; Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF02; WHO ATC D10AF52; WHO ATC J01FA01; WHO ATC S01AA17

Repurposing investigation

Erythromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 17 of 25 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 6 of 6 lab records
Open Erythromycin in ChEMBL Registered studies below
Show the 32 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erythromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

    NCT04390152 · start 2020-01-13

    Registered record
    Registry ID
    NCT04390152
    Conditions
    Acute Respiratory Distress Syndrome
    Interventions
    Wharton's jelly derived Mesenchymal stem cells.; Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-01-13
    Completion
    2022-03-03
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Distress Syndrome
    InterventionWharton's jelly derived Mesenchymal stem cells.; Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Efficacy of Volume Ventilation in Patients With Acute Respiratory Failure at Risk of Obstructive Apneas or Obesity Hypoventilation

    NCT04131660 · start 2019-12-04

    Registered record
    Registry ID
    NCT04131660
    Conditions
    Acute Respiratory Failure; Hypercapnic Respiratory Failure; Respiratory Acidosis; Obesity; Hypoventilation Syndrome; Apnea, Obstructive
    Interventions
    AVAPS-AE mode during NIV; S/T mode during NIV
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2019-12-04
    Completion
    2021-06-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Failure; Hypercapnic Respiratory Failure; Respiratory Acidosis; Obesity +2 more
    InterventionAVAPS-AE mode during NIV; S/T mode during NIV
    PhaseNot applicable
    Registry statusTerminated

  • Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

    NCT03925480 · start 2019-07-01

    Registered record
    Registry ID
    NCT03925480
    Conditions
    Bacterial Infections
    Interventions
    Azithromycin 500 mg Oral Tablet x 4; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2023-02-28
    Enrolment
    2,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionAzithromycin 500 mg Oral Tablet x 4; Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • Laser Therapy Versus Narrow Band Ultraviolet B for the Treatment of Acne Vulgaris

    NCT04254601 · start 2018-04-01

    Registered record
    Registry ID
    NCT04254601
    Conditions
    Skin Diseases
    Interventions
    Narrow band ultraviolet B.; topical erythromycin cream 2% (Akne-Mycin- Egypt)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-04-01
    Completion
    2019-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases
    InterventionNarrow band ultraviolet B.; topical erythromycin cream 2% (Akne-Mycin- Egypt)
    PhaseNot applicable
    Registry statusCompleted

  • S. Aureus Decolonization in HPN Patients.

    NCT03173053 · start 2018-02-08

    Registered record
    Registry ID
    NCT03173053
    Conditions
    Staphylococcus Aureus; Motility Disorder
    Interventions
    Doxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin; Clarithromycin; Ciprofloxacin; Fusidic Acid; Rifampin; Chlorhexidine; Mupirocin; Betadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2021-10-14
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus; Motility Disorder
    InterventionDoxycycline; Trimethoprim; Sulfamethoxazole/trimethoprim; Clindamycin +7 more
    PhaseNot applicable
    Registry statusTerminated

  • Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System

    NCT03345992 · start 2017-12-15

    Registered record
    Registry ID
    NCT03345992
    Conditions
    Sepsis; Pneumonia; Gram-Negative Bacteria Infection; Multiple Organ Failure; Respiratory Distress Syndrome; Mortality; Biomarkers
    Interventions
    Clarithromycin; Water for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2020-12-19
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Pneumonia; Gram-Negative Bacteria Infection; Multiple Organ Failure +3 more
    InterventionClarithromycin; Water for injection
    PhasePhase 3
    Registry statusCompleted

  • Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

    NCT02988089 · start 2017-04-20

    Registered record
    Registry ID
    NCT02988089
    Conditions
    Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventions
    Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone; amoxicillin and furazolidone or amoxicillin and tetracycline; amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04-20
    Completion
    2017-09
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    InterventionClarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone +2 more
    PhasePhase 4
    Registry statusUnknown

  • Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

    NCT02986451 · start 2016-12

    Registered record
    Registry ID
    NCT02986451
    Conditions
    Relapse/Refractory Multiple Myeloma
    Interventions
    clarithromycin; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-12
    Completion
    2019-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapse/Refractory Multiple Myeloma
    Interventionclarithromycin; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusWithdrawn

  • Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole

    NCT02998437 · start 2016-12

    Registered record
    Registry ID
    NCT02998437
    Conditions
    Drug Interaction Potentiation
    Interventions
    Ilaprazole 10mg; Clarithromycin 500mg; Amoxicillin 500 Mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12
    Completion
    2017-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    InterventionIlaprazole 10mg; Clarithromycin 500mg; Amoxicillin 500 Mg
    PhasePhase 1
    Registry statusCompleted

  • Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication

    NCT02934152 · start 2016-10

    Registered record
    Registry ID
    NCT02934152
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    H pylori eradication; H pylori eradication timing
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2019-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionH pylori eradication; H pylori eradication timing
    PhasePhase 4
    Registry statusUnknown

  • Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment

    NCT02732249 · start 2016-04-01

    Registered record
    Registry ID
    NCT02732249
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole; Bismuth Potassium Citrate; Clarithromycin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-09-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole; Bismuth Potassium Citrate; Clarithromycin; Metronidazole
    PhasePhase 4
    Registry statusCompleted

  • HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

    NCT02875314 · start 2015-09

    Registered record
    Registry ID
    NCT02875314
    Conditions
    Medulloblastoma; Central Nervous System Embryonal Tumors
    Interventions
    Induction; Single Cycle Intensive Chemotherapy; Tandem 3 Cycle Intensive Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2015-09
    Completion
    2030-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedulloblastoma; Central Nervous System Embryonal Tumors
    InterventionInduction; Single Cycle Intensive Chemotherapy; Tandem 3 Cycle Intensive Chemotherapy
    PhasePhase 4
    Registry statusActive not recruiting

  • To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

    NCT02807051 · start 2014-09

    Registered record
    Registry ID
    NCT02807051
    Conditions
    Drug Interaction Study
    Interventions
    Pacritinib; Clarithromycin; Pacritinib and Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09
    Completion
    2014-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Study
    InterventionPacritinib; Clarithromycin; Pacritinib and Clarithromycin
    PhasePhase 1
    Registry statusCompleted

  • Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.

    NCT02017379 · start 2014-06

    Registered record
    Registry ID
    NCT02017379
    Conditions
    Upper Gastrointestinal Bleeding
    Interventions
    Erythromycin; Metoclopromide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2014-06
    Completion
    2014-09
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUpper Gastrointestinal Bleeding
    InterventionErythromycin; Metoclopromide
    PhaseNot applicable
    Registry statusTerminated

  • Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

    NCT04870138 · start 2013-03-10

    Registered record
    Registry ID
    NCT04870138
    Conditions
    Gonococcal Infection
    Interventions
    Azithromycin; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26; Neisseria gonorrhoeae strain FA7527
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-03-10
    Completion
    2015-04-28
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonococcal Infection
    InterventionAzithromycin; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26 +1 more
    PhasePhase 1
    Registry statusCompleted